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Available online 12 March 2008Hexose-6-phosphate dehydrogenase (H6PDH) has been shown to stimulate 11β-hydroxysteroid
dehydrogenase type 1 (11β-HSD1)-dependent local regeneration of active glucocorticoids. Here, we show
that coexpressionwith H6PDH results in a dramatic shift from 11β-HSD1 oxidase to reductase activity without
affecting the activity of the endoplasmic reticular enzyme 17β-HSD2. Immunoprecipitation experiments
revealed coprecipitation of H6PDH with 11β-HSD1 but not with the related enzymes 11β-HSD2 and 17β-
HSD2, suggesting a speciﬁc interaction between H6PDH and 11β-HSD1. The use of the 11β-HSD1/11β-HSD2
chimera indicates that the N-terminal 39 residues of 11β-HSD1 are sufﬁcient for interaction with H6PDH. An
important role of the N-terminus was indicated further by the signiﬁcantly stronger interaction of 11β-HSD1
mutant Y18-21A with H6PDH compared to wild-type 11β-HSD1. The protein–protein interaction and the
involvement of the N-terminus of 11β-HSD1 were conﬁrmed by Far-Western blotting. Finally, ﬂuorescence
resonance energy transfer (FRET) measurements of HEK-293 cells expressing ﬂuorescently labeled proteins
provided evidence for an interaction between 11β-HSD1 and H6PDH in intact cells. Thus, using three different
methods, we provide strong evidence that the functional coupling between 11β-HSD1 and H6PDH involves a
direct physical interaction of the two proteins.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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The 11β-HSD1-dependent local activation of glucocorticoids
recently attracted much attention because of its implications in the
pathogenesis of metabolic diseases including obesity, insulin resis-
tance and type 2 diabetes, atherosclerosis and hypertension [1–3].
Inhibition of the production of active 11β-hydroxyglucocorticoids
(cortisol, corticosterone) from inactive 11-ketoglucocorticoids (corti-
sone, 11-dehydrocorticosterone) by 11β-HSD1 is currently considered
as a novel promising therapeutic approach for these disorders. This
strategy implies that 11β-HSD1 functions as a reductase.
In tissue homogenates or upon puriﬁcation 11β-HSD1 is a
bidirectional enzyme catalyzing both the oxidation of 11β-hydro-
xyglucocorticoids and the reduction of 11-ketoglucocorticoids [4,5].
Although 11β-HSD1 acts as a dehydrogenase in some cells, such as
preadipocytes and testicular Leydig cells, it predominantly functions
as a reductase in most cell types including metabolically relevant
hepatocytes and mature adipocytes [6–10]. 11β-HSD1 is an endo-ology, Department of Pharma-
e 50, 4056 Basel, Switzerland.
att).
study.
l rights reserved.plasmic reticulum (ER) membrane protein with a single N-terminal
transmembrane helix and its catalytic moiety facing the lumenal
compartment [11–13]. It preferentially utilizes NADP(H) as cofactor
[14,15], whereby both the topology and the cofactor availability can be
considered as important determinants for the reaction direction of
11β-HSD1 [13,16]. Because the ER membrane is almost impermeable
for NADP(H), the reaction direction of 11β-HSD1 depends on the
intralumenal availability of the cofactor [17].
In the ER lumen, cofactor NADPH is generated by the enzyme
H6PDH [18,19], which is an isoform of the well known and extensively
studied glucose-6-phosphate dehydrogenase (G6PDH) that catalyzes
the ﬁrst and rate-limiting step of the pentose phosphate cycle in the
cytoplasm. Distinct from G6PDH, H6PDH not only utilizes glucose-6-
phosphate as a substrate but also other hexose-6-phosphates and
sugars. It was demonstrated that H6PDH, depending on the substrate,
exhibits different preference for NADP+ andNAD+, respectively [20,21].
At physiological pH and with the major substrate glucose-6-phos-
phate, the generation of NADH by puriﬁed H6PDH is approximately
30% that of NADPH [21]. Compared with the activity of G6PDH and the
production of NADPH in the cytoplasm, the estimated ER-lumenal
NADPH production by H6PDH is relatively low and contributes only a
few percent to the total cellular NADPH formation [22].
The functional role of H6PDH remained obscure until recently
when a number of studies indicated that NADPH generation by
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tion of active glucocorticoids [23–27]. In a previous study, using the
HEK-293 cell system, we demonstrated that coexpression of 11β-
HSD1with H6PDH resulted in amore than 20-fold increase in the ratio
of reductase/dehydrogenase activity of 11β-HSD1 [24]. However, the
molecular mechanism underlying the H6PDH-dependent stimulation
of 11β-HSD1 reductase activity remained unclear, and the question
arose whether H6PDH enhanced 11β-HSD1 reductase activity by
increasing the overall concentration of NADPH and NADH in the ER
lumen or whether it stimulates 11β-HSD1 by physical interaction and
direct delivery of cofactor NADPH for cortisone reductase activity [16].
To investigate the mechanism by which H6PDH stimulates 11β-
HSD1 reductase activity, we employed the HEK-293 cell system,
which lacks the endogenous expression of 11β-HSD1 and H6PDH,
thus allowing the expression of recombinant wild-type and mutant
11β-HSD1 and other short-chain dehydrogenase/reductase enzymes
in the presence or absence of H6PDH, followed by analyses of
enzymatic activity, intracellular localization and protein–protein
interactions.
2. Experimental procedures
2.1. Chemicals and reagents
Cell culture reagents were purchased from Invitrogen (Carlsbad,
CA), [1,2,6,7-3H]-cortisol, [2,4,6,7-3H]-estrone and [2,4,6,7-3H]-estra-
diol were from Amersham Health AG (Wädenswil, Switzerland) and
[1,2,6,7-3H]-cortisone from American Radiolabeled Chemicals (St.
Louis, MO). The unlabeled steroid hormones were from Steraloids
(Wilton, NH). All other chemicals were from Fluka AG (Buchs,
Switzerland) and were of the highest grade available.
2.2. Cell culture and transient transfection
HEK-293 (human embryonic kidney) cells were grown at 37 °C
under 5% carbon dioxide in Dulbecco's modiﬁed Eagle medium
(DMEM) supplemented with 10% fetal calf serum, 4.5 g/L glucose,
50 U/mL penicillin/streptomycin, and 2 mM glutamine. Cells were
grown to 90% conﬂuence and split 1:5 every third day for propagation
or 1:2 24 h prior to transfection according to the calcium phosphate
precipitation method. For transient expression human 11β-HSD1 and
11β-HSD2 containing a C-terminal FLAG-epitope [11], human 17β-
HSD1 and 17β-HSD2 with a C-terminal histidine-tag [28] or human
H6PDH and G6PDH with a C-terminal myc epitope [24] cloned into
pcDNA3 were used. The construction of the chimera 12F (residues 1–
39 of 11β-HSD1 and 88–405 of 11β-HSD2) and 21F (amino acids 1–87
of 11β-HSD2 and 40–292 of 11β-HSD1) and mutant Y18-21A
(substitutions of tyrosine residues 18–21 to alanine) was described
previously [11]. HEK-293 cells grown in 10 cm dishes were transfected
with 8 μg of SDR expression plasmid and 8 μg of plasmid for H6PDH,
G6PDH or pcDNA3 control according to the calcium phosphate
precipitation method.
2.3. Activity assays
Enzyme activities were measured essentially as described earlier
[28]. Brieﬂy, cells were transferred 24 h post-transfection in 96 well
plates followed by incubation for another 24 h. The rates of conversion
of cortisol to cortisone, estradiol to estrone and the reverse reactions
were determined by incubation of the cells at 37 °C and 5% CO2 for
different time intervals ranging from 0.5 to 4 h (to reach a ﬁnal
conversion between 10–30%) in the presence of 10 nM of the
corresponding radiolabeled steroid ([1,2,6,7-3H]-cortisol, [1,2,6,7-
3H]-cortisone, [2,4,6,7-3H]-estrone or [2,4,6,7-3H]-estradiol) and
various concentrations of unlabeled substrate (10–1990 nM). The
reactions were stopped by adding an excess of unlabeled steroids inmethanol, followed by separation of the steroids using thin-layer
chromatography and scintillation counting. The activities were
compared by calculating Kcat (Vmax/Km) and normalizing Kcat values
to the values obtained for the oxidase reaction of the corresponding
SDR enzyme in the absence of H6PDH.
2.4. Coimmunoprecipitation and immunoblotting
For coimmunoprecipitation experiments HEK-293 cells were split
in 10 cm dishes and transfected 24 h later with the constructs
indicated. The cells were then incubated for 48 h at 37 °C to achieve
sufﬁcient protein expression, followed bywashing twice with PBS and
lysis for 1 h at 4 °C in a buffer containing 50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA and 1% Triton X-100. Cell lysates (1 mg of
total proteins) were then incubated for 3 h with 40 μl mouse
monoclonal anti-FLAG antibody M2-coupled agarose beads (A2220,
Sigma-Aldrich, Buchs, Switzerland) to bind FLAG-tagged 11β-HSD1,
11β-HSD2 or chimeric proteins. Alternatively, HIS-Select™ Nickel
Afﬁnity Beads (E3528, Sigma-Aldrich) were used to bind histidine-
tagged 17β-HSD1 and 17β-HSD2. The beads were then washed four
times with TBS, and the precipitated protein was eluted with SDS-
PAGE sample buffer without dithiothreitol. After separation on SDS-
PAGE, the proteins were transferred to a nitrocellulose membrane
followed by immunodetection with primary antibodies against the
corresponding tag (mouse anti-FLAG M2 antibody, Sigma-Aldrich;
mouse Tetra-His antibody, Qiagen; or rabbit anti-myc antibody,
Abcam, Cambridge, UK) and secondary horse-radish peroxidase
(HRP)-conjugated antibodies (HRP-goat anti-mouse IgG (BioRad)
and HRP-goat anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz,
CA). The secondary antibodies were visualized by enhanced chemi-
luminescence (ECL Plus™) Western blotting detection reagents
(Amersham Health AG).
2.5. Afﬁnity puriﬁcation and enzyme activity of H6PDH
HEK-293 cells stably transfected with the myc-tagged H6PDH
construct were rinsed twice with PBS, and the protein was
immunopuriﬁed with anti-myc antibody-coupled agarose beads
(A7470, Sigma-Aldrich) according to the protocol of the manufacturer.
Bound protein was eluted from the beads by incubation with 100 μg/
ml c-myc peptide (M 2435, Sigma-Aldrich) in 50 mM Tris–HCl pH 7.4
for 30 min at 25 °C. Analysis by SDS-PAGE and Coomassie-staining
revealed a single protein band of approximately 90 kDa, correspond-
ing to H6PDH. The puriﬁed protein was supplemented with 1 mg/ml
BSA and 15% glycerol, snap-frozen in dry ice/ethanol and stored at
−70 °C. The activity of H6PDH was measured by ﬂuorometric
detection of NADPH formation in the presence of 100 μM glucose-6-
phosphate and 250 μM NADP+ as described previously [25].
2.6. Far-Western blotting
Far-Western blotting was performed essentially as described [29].
A total amount of 1mgof total protein fromHEK-293 cells transfected
with wild-type or mutant 11β-HSD1 or with pcDNA3 control was
subjected to immunoprecipitation followed by SDS-PAGE and
electrotransfer to a nitrocellulose membrane. The membrane was
then incubated for 2 h in blocking buffer 1 (0.05% Tween-20 in PBS)
and for another 2 h in blocking buffer 2 (1% BSA in PBS) to allow
partial renaturation of the proteins on the nitrocellulose membrane.
The membrane was brieﬂy washed with PBS followed with incuba-
tion for 2 h with the afﬁnity-puriﬁed H6PDH diluted in 50 mM Tris–
HCl, pH 7.4. The membrane was then washed 4 times with PBS and
blocked for 1 h in TBS supplemented with 2% milk. Binding of myc-
tagged H6PDH was detected with rabbit anti-myc antibody (Abcam)
and secondary HRP-conjugated goat anti-rabbit IgG (Santa Cruz) as
described above.
Fig. 1. Effect of H6PDH on oxidase and reductase activities of 11β-HSD1 and related
SDRs. HEK-293 cells were transfected with plasmids for 11β-HSD1 (A), 17β-HSD2 (B),
11β-HSD2 (C) or 17β-HSD1 (D) together with pcDNA3 control plasmid or H6PDH
expression vector. Oxidase activities (black bars) were measured by determining the
conversion of cortisol to cortisone (A,C) or estradiol to estrone (B,D) in the presence of
various concentrations of substrate. For reductase activities (white bars), the reverse
reactions were measured. The y-axis displays calculated, apparent Kcat (Vmax/Km) values
as a percentage of apparent Kcat of the oxidase reaction in the absence of H6PDH. Data
represent mean±SD from four independent experiments. ⁎⁎pb0.01; ⁎⁎⁎pb0.001.
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Fusion proteins of H6PDH with EYFP were generated by cloning
human H6PDH into EcoRI and XbaI endonuclease restriction sites of
pEYFP-C1 or into EcoRI and AgeI sites of pEYFP-N1 (Clontech
Laboratories, Mountain View, CA) to obtain H6PDH–EYFP. To generate
11β-HSD1–ECFP, human 11β-HSD1 was inserted into the NheI
endonuclease restriction site of pECFP-C1 (Clontech). The ECFP–11β-
HSD1 chimerawas not constructed because the ECFPmoiety would be
oriented toward the cytosolwhereas the catalytic domain of 11β-HSD1
would face the ER lumen. HEK-293 cells were transfected with
different combinations of expression plasmids, grown for 24 h and
ﬁxed in a buffer containing 150mMsodiumphosphate, pH7.4,120mM
sucrose and 4% paraformaldehyde. Acceptor photobleaching was used
to assess FRET efﬁciency on a Zeiss LSM510 confocal microscope
equipped with a 63×/1.4 oil immersion objective. ECFP was excited
with a 458 nm laser line, emission measured with a BP470-500 ﬁlter.
EYFP was excited with a 514 nm laser line, emission measured with a
LP530 ﬁlter. For each measure we made sure that EYFP bleaching was
over 90%, and FRET efﬁciency (E) was calculated after background
subtraction and CFP bleaching correction as follows: E=(ID−IDA)/ ID,
where ID and IDA are ECFP intensities in the bleached region after and
before photobleaching of EYFP, respectively. For each condition, 4 to 10
cells were assessed.
2.8. Determination of the parameters of H6PDH peptides for quantiﬁcation
by LC-multiple reaction monitoring (MRM)
The band corresponding to overexpressedH6PDHafter separation of
proteins by SDS-PAGE was sliced, washed and in-gel digested with
trypsin overnight at 37 °C. Tryptic peptides were separated by nano-
HPLC (Agilent 1100 nanoLC system, Agilent Technologies, Santa Clara,
CA) coupled to a 4000 Q TRAP mass spectrometer (Applied Biosystems,
Foster City, CA). The LC system was equipped with a capillary column
with an integrated nanospray tip (75 μm i.d.×100 mm, Spectronex,
Basel, Switzerland) ﬁlled with MagicC18 (Michrom Bioresources, Inc.,
Auburn, CA). Solvent A consisted of 0.1% formic acid/2% acetonitrile,
solventBwas composed of 0.1% formic acid/80%acetonitrile. Elutionwas
performedwith a gradientof 0 to 45%solvent B in 30min at aﬂowrate of
300 nL/min. Samples were loaded on a Peptide CapTrap (Michrom
BioResources). In the IDA mode the mass spectrometer cycled through
six analyses, one full-scanMS experiment, and one enhanced resolution
experiment for the four most intense peaks followed by four enhanced
product ion experiments. H6PDH peptides were determined searching
UniProt data base using Mascot (Matrix Science).
2.9. Quantiﬁcation of H6PDH in cells by LC-MRM
MRM-relevant data as transition values, charge state and retention
time of H6PDH and the six most abundant proteins were extracted
from the Mascot result ﬁle using MRM Buddy, a software developed at
the FMI (Novartis Research Foundation). Whole cells were lyzed in
lysis buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, Complete protease
inhibitors (Roche Diagnostics, Rotkreuz, Switzerland), 1% w/v dithio-
threitol), and the proteins were precipitated using chloroform/
methanol [30] and resuspended in 100 μl 47 mM Tris–HCl, pH9.0.
The cysteines were reduced with dithiothreitol, alkylated with
iodoacetamide and digested with trypsin overnight at 37 °C. The
digest was 40-times diluted with solvent A and analyzed by LC-MRM
keeping the HPLC settings constant (see above). Quantitative data
were evaluated using Analyst 1.4.1.
2.10. Statistical analysis
To estimate apparent Kcat, apparent Vmax and Km values of the
enzymatic reactions were calculated by nonlinear regression usingData Analysis Toolbox (MDL Information Systems Inc., Nashville, TN,
USA) assuming ﬁrst-order rate kinetics. Data represent mean±SD of at
least four independent experiments.
3. Results
3.1. Effect of cofactor regenerating enzymes on the reaction direction of
11β-HSD1 and related SDR enzymes
In a previous study, we have shown that H6PDH causes 11β-HSD1
to function as a reductase [24]. In line with the previous ﬁndings,
Fig. 1A shows a signiﬁcant stimulation of 11β-HSD1 reductase activity
and a concomitant loss of oxidase activity upon coexpression with
H6PDH in intact HEK-293 cells, resulting in an approximately 20-fold
increased ratio of 11β-HSD1 reductase/oxidase activity. In contrast,
coexpression with H6PDH had no signiﬁcant effect on the activity of
the endoplasmic reticular enzyme 17β-HSD2 [31,32], which utilizes
NADH and predominantly catalyzes the oxidation of estradiol to
estrone (Fig. 1B). 17β-HSD2 reductase activity even tended to decrease
in the presence of H6PDH. As expected, coexpression with H6PDH
neither altered the activity of 11β-HSD2 (Fig. 1C) nor the reduction of
estrone to estradiol by 17β-HSD1 (Fig. 1D), two enzymes facing the
cytoplasm. The reason for the decreased 17β-HSD1-dependent
oxidase activity remains unclear.
Since the ER membrane is considered to be impermeable for
pyridine nucleotides, we investigated a potential effect of G6PDH on
the selected SDR enzymes. Neither the two ER-lumenally oriented
enzymes 11β-HSD1 and 17β-HSD2 nor 11β-HSD2 and 17β-HSD1,
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(data not shown). The fact that G6PDH did not stimulate the NADPH-
dependent conversion of estrone to estradiol suggests that cofactor
availability under the conditions used was not a limiting factor for
17β-HSD1 function.
These observations supported our hypothesis that a more speciﬁc
mechanism might be responsible for the regulation of 11β-HSD1
function by H6PDH than simply an increase in intralumenal NADPH
concentration.
3.2. Assessment of endogenous H6PDH expression in HEK-293 cells
Because H6PDH-deﬁcient mice were reported to have lost the
ability to convert 11-dehydrocorticosterone to corticosterone [26],
and we found that HEK-293 cells transfected only with 11β-HSD1
catalyzed the reductase and oxidase reactions with similar efﬁciencies
(Fig. 1A), we investigated whether the observed reductase activity in
HEK-293 cells might be due to endogenous H6PDH expression. Real-
time RT-PCR experiments revealed a very low H6PDH mRNA
expression level in untransfected HEK-293 cells with less than 100
copies/cell (data not shown, [24]). Western blot analysis, using a rabbit
polyclonal antiserum against the lactonase domain (residues 539–
791) of human H6PDH [33], yielded a band at approximately 90 kDa in
cells overexpressing H6PDH, whereas no signal could be detected in
untransfected HEK-293 cells (data not shown).
As an additional, sensitive and antibody-independent method for
protein detection and quantiﬁcation, we applied multiple reaction
monitoring (MRM) analysis. The MRM analysis of peptide transitions
speciﬁc for H6PDH resulted in strong signals in H6PDH overexpressingFig. 2. Analysis of H6PDHprotein expression inHEK-293 cells. An amount of 2 μg of tryptic diges
HEK-293 cells (C and D) were analyzed using MRM. (A) and (C) show signals recorded for the b
style belongs to the same peptide transition). (B) and (D) represent the signals of the three H6
(same peptide transitions share the same curve style). Arrows indicate the expected positionscells and no peaks for untransfected HEK-293 cells (Fig. 2). The signal
to noise ratio of the most intense H6PDH signals is in the range of
1000, indicating an at least 1000 times lower H6PDH expression level
in untransfected HEK-293 cells. These results suggest that in the HEK-
293 cells used in the present study, H6PDH is either absent or
expressed at very low levels that are unlikely to be biologically
relevant. The HEK-293 cells expressing recombinant 11β-HSD1 and
H6PDH had enzymatic activities comparable with those of freshly
isolated rat hepatocytes and approximately two-fold higher activities
compared with fully differentiated 3T3-L1 adipocytes, suggesting that
the enzymes were not aberrantly overexpressed.
3.3. Coimmunoprecipitation of 11β-HSD1 and H6PDH
To investigate whether a direct protein–protein interaction might
be responsible for the functional coupling of 11β-HSD1 andH6PDH,we
performed coimmunoprecipitation experiments. FLAG-tagged 11β-
HSD1 and myc-tagged H6PDH were coexpressed in HEK-293 cells,
followed by immunoprecipitation of 11β-HSD1 with agarose beads
that were coupled with anti-FLAG antibody M2 (Sigma-Aldrich).
H6PDH coprecipitated with 11β-HSD1 but not with 11β-HSD2 or 17β-
HSD2 (Fig. 3A). As controls, we incubated anti-FLAG coupled agarose
beads with lysates of untransfected cells or of cells transfected with
myc-tagged H6PDHonly. The proteins bound to the beadswere eluted,
separated by SDS-PAGE and analyzed by immunoblotting using an
anti-myc antibody. As shown in lane 1 and 2, no band was detected at
90 kDa in these control experiments, indicating that H6PDH did not
bind unspeciﬁcally to the beads and that the band identiﬁed in lane 3
corresponds to H6PDH that was coprecipitated with 11β-HSD1.ted total cell protein extracts of cells overexpressingH6PDH (A and B) and of untransfected
ackground protein actin, demonstrating the good reproducibility of the method (same line
PDH-speciﬁc peptides that were recorded in the same run generating the signals for actin
of the H6PDH-speciﬁc signals of endogenously expressed protein in HEK-293 cells.
Fig. 3. Coimmunoprecipitation of H6PDHwith 11β-HSD1. HEK-293 cells were transfected
with the plasmids indicated, followed by immunoprecipitation (IP) of FLAG-tagged 11β-
HSD1 and 11β-HSD2 with anti-FLAG antibody-coupled agarose beads or histidine-tagged
17β-HSD2with histidine nickel afﬁnity beads. Bound proteinswere eluted from the beads,
subjected to Western blotting, and coprecipitated H6PDH was visualized with anti-myc
antibody. (A) Interaction of H6PDHwith 11β-HSD1. The experiments with 11β-HSD1,11β-
HSD2 and 17β-HSD2were performed independently. (B) TheN-terminal 39 amino acids of
11β-HSD1are sufﬁcient for interactionwithH6PDH. (C)H6PDHshows stronger interaction
with mutant Y18-21A than with 11β-HSD1. One out of three comparable and inde-
pendently performed experiments is shown.
Fig. 4. Comparison of oxidase and reductase activities of wild-type 11β-HSD1 and
mutant Y18-21A. HEK-293 cells were transfectedwith plasmids for 11β-HSD1 ormutant
Y18-21A and either pcDNA3 control plasmid or H6PDH expression vector. Oxidase
activities (black bars) were measured by determining the conversion of cortisol to
cortisone at various concentrations of substrate. For reductase activities (white bars), the
reverse reaction was measured. The y-axis displays calculated apparent Kcat (Vmax/Km)
values as a percentage of apparent Kcat of the reductase reaction of wild-type enzyme in
the absence of H6PDH. Data represent mean±SD from four independent experiments.
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with H6PDH
In an attempt to deﬁne the region of 11β-HSD1 that is responsible
for the interaction with H6PDH, we applied a previously described
chimera between 11β-HSD1 and 11β-HSD2, where the N-terminal
membrane anchor sequences, that are located upstream of the
conserved pyridine nucleotide binding sites, were exchanged [11].
The chimera containing the N-terminal 39 amino acids of 11β-HSD1
and residues 88–405 of 11β-HSD2 (12F) retained its ability to co-
precipitate H6PDH (Fig. 3B). In contrast, the chimera consisting of the
N-terminal region of 11β-HSD2 and residues 40–292 of 11β-HSD1
(21F) did not interact with H6PDH. Wild-type and chimeric proteins
were equally well expressed (data not shown, see [11]). This indicates
that the N-terminal part of 11β-HSD1 is involved in the interaction
with H6PDH.
In addition, we studied the impact of mutations in the tyrosine
motif of the N-terminal transmembrane helix on the interaction with
H6PDH. Mutant Y18-21A, where the four tyrosine residues at
positions 18–21 were substituted by alanine, showed substantiallystronger coprecipitation of H6PDH (Fig. 3C), further indicating a
crucial role of the N-terminus of 11β-HSD1 for the interaction with
H6PDH. Mutant Y18-21A and wild-type 11β-HSD1 showed compar-
able protein expression levels and intracellular localization as
determined by semi-quantitative immunoblotting analysis and ﬂuor-
escence microscopy (data not shown, see [11]).
Analysis of the mutant Y18-21A enzyme activity revealed an
approximately 5-times lower ability to convert cortisone compared
with wild-type 11β-HSD1. Unlike the wild-type enzyme, mutant Y18-
21A almost exclusively catalyzed the reduction of cortisone in the
absence of H6PDH, and coexpressionwith H6PDH did not signiﬁcantly
stimulate its reductase activity, despite the stronger interaction (Fig. 4).
3.5. Immunopuriﬁcation of H6PDH and Far-Western blotting
To further conﬁrm the interaction between 11β-HSD1 and H6PDH,
we performed Far-Western blotting experiments. Myc-tagged H6PDH
was immunopuriﬁed by a single-step puriﬁcation using anti-myc
antibody-coupled agarose beads (Sigma-Aldrich), followed by elution
with 100 μg/ml c-myc peptide. The eluate contained a single protein
bandof approximately 90kDa, corresponding toH6PDH, thatwasabsent
when cells were transfected with pcDNA3 control vector instead of
H6PDH expression plasmid (Fig. 5A). The puriﬁed H6PDH was
catalytically active (Fig. 5B), indicating that it retained its native
conformation. Puriﬁed H6PDH was then incubated with nitrocellulose
membranes on which different wild-type and chimeric 11β-HSD1
proteins were transferred after SDS-PAGE. After removal of unspeciﬁc
binding by washing, bound H6PDH was detected by anti-myc antibody.
A band corresponding to the expected size of 11β-HSD1was detected in
the lane where wild-type 11β-HSD1 was loaded and a stronger signal
was obtained for mutant Y18-21A (Fig. 5C), in line with the immuno-
precipitation experiments. H6PDH did not bind to chimeric 21F protein
but yielded a signal with chimeric 12F protein, although the intensity
was weaker than expected from the immunoprecipitation experiment.
3.6. Evidence for the interaction between 11β-HSD1 and H6PDH in intact
cells by ﬂuorescence resonance energy transfer (FRET)
Previously, we showed that both 11β-HSD1 and H6PDH are located
at the lumenal surfaceof theERmembrane [24].However, localization in
the same cellular compartment did not answer the question whether
the two proteins also physically interact with each other. Therefore, we
constructed expression plasmids for 11β-HSD1 fused C-terminally to
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coexpressed 11β-HSD1–ECFP with the corresponding fusion protein of
H6PDH and EYFP. As a positive FRET control, a direct fusion of ECFP to
EYFP [34] was applied. The ECFP–EYFP fusion protein yielded a FRET
signal of 19.9±1.3%, whereas the coexpression of 11β-HSD1–ECFP with
EYFP as a negative control was 2.5±0.3% (Fig. 6). Signiﬁcant FRET signals
of 5.8±1% and 8.0±2.0% were obtained for 11β-HSD1–ECFP with
H6PDH–EYFP and 11β-HSD1–ECFP with EYFP–H6PDH, respectively,Fig. 5. Puriﬁcation of H6PDH and Far-Western blot. (A) Coomassie-stained SDS-PAGE of
puriﬁed H6PDH. Myc-tagged H6PDH was expressed in HEK-293 cells and subjected to a
single-step puriﬁcation using anti-myc antibody-coupled agarose beads. Lane 1,
molecular weight marker; lane 2, crude lysate of HEK-293 cells transfected with
H6PDH; lane 3, eluate of beads incubated with lysate of HEK-293 cells transfected with
pcDNA3 control vector; lane 4, eluate of beads incubated with lysate of cells transfected
with H6PDH. (B) Enzyme activity of the puriﬁed H6PDH. H6PDH activity was measured
by spectrometric detection of NADPH formation in the presence of 100 μM glucose-6-
phosphate and 250 μMNADP+. The eluate from beads incubated with lysate of HEK-293
cells transfected with pcDNA3 control vector was inactive, whereas eluate derived from
H6PDH expressing HEK-293 cells readily catalyzed the formation of NADPH. (C) Far-
Western blotting. Lysates from HEK-293 cells transfected with the constructs indicated
were subjected to SDS-PAGE and proteins transferred onto nitrocellulose membranes.
The membrane was incubated with puriﬁed myc-tagged H6PDH, washed and bound
protein detected with anti-myc antibody.
Fig. 6. Interaction of 11β-HSD1 and H6PDH in intact cells. HEK-293 cells were transfected
with ECFP–EYFP, serving as a positive control for complete interaction, or co-transfected
withN- or C-terminal fusions ofH6PDHandEYFP togetherwith 11β-HSD1–ECFP.11β-HSD1
co-transfected with EYFP was used as negative control. Acceptor photobleaching was used
to assess FRETefﬁciency. For each condition, 4 to 10 cells were assessed. Results are shown
as mean FRET efﬁciency±S.E.M.whereby the presence or absence of cortisone did not alter the FRET
signal (data not shown). These results strongly support an interaction of
11β-HSD1 and H6PDH in intact cells.
4. Discussion
The local control of active to inactive glucocorticoids by 11β-HSD
enzymes allows a highly tissue- and cell-speciﬁc response to
glucocorticoids and plays an important role in the regulation of
energy metabolism, immune system, brain function as well as cell
proliferation and differentiation. While 11β-HSD2 exclusively cata-
lyzes the oxidation of active endogenous glucocorticoids, 11β-HSD1
can act both as a dehydrogenase or a reductase, depending on the
absence or presence of H6PDH [3,35]. Coexpression with H6PDH adds
another level of ﬁne-tuning in the regulation of tissue-speciﬁc
glucocorticoid action.
In the present study, using coimmunoprecipitation, Far-Western
and FRET experiments, we demonstrate a direct protein–protein
interaction between 11β-HSD1 and H6PDH both in cell homogenates
and in intact cells. A direct interaction with H6PDH allows the supply
of NADPH in close proximity to 11β-HSD1 for the efﬁcient reduction of
cortisone to cortisol despite a rather oxidative environmentwithin the
ER lumen. The interaction allows H6PDH to regulate 11β-HSD1
function without the need to change overall ER-lumenal NADPH
concentrations. In contrast to its effect on 11β-HSD1, H6PDH did not
stimulate the reductase activity of 17β-HSD2, which utilizes NADH
and whose catalytic domain protrudes into the ER lumen. It was
reported that puriﬁed H6PDH can generate both NADH and NADPH,
although with an approximately three-fold preference for the
formation of the latter [21]. If H6PDH increases overall intralumenal
concentrations of both NADPH and NADH, one would expect to see a
stimulation of the NADH-dependent reduction of estrone to estradiol
by 17β-HSD2 and a decreased reverse reaction. However, it is unclear
at present whether in vivo such a possible increase in NADH
concentration in the ER lumen occurs and whether it could be
effective on 17β-HSD2 activity. In analogy, in the cytoplasm, over-
expression of G6PDH did not alter 11β-HSD2 or 17β-HSD1 activity,
suggesting that overall cytoplasmic NADPH concentration did not
signiﬁcantly change. Although these observations do not rule out an
effect of G6PDH and H6PDH on overall cofactor concentration in the
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respect to the high glucose medium used in the present study for
culturing cells, they suggest that the direct interaction with H6PDH
allows a more subtle regulation of 11β-HSD1 function.
Measurements with hepatic tissue explants from H6PDH-deﬁcient
mice showed a 60% decreased generation of NADPH and signiﬁcantly
increased dehydrogenase activity [36]. The observation that 11β-
HSD1 switches from a reductase to a dehydrogenase in H6PDH-
deﬁcient mice demonstrates the importance of H6PDH-dependent
generation of ER-lumenal NADPH for cortisol production by 11β-
HSD1. H6PDH-deﬁcientmice show abnormal glucose homeostasis and
disturbances in the hypothalamic–pituitary–adrenal axis [26,36,37].
In addition, H6PDH-deﬁcient mice suffer from skeletal myopathy,
characterized by a switch from type II to type I ﬁbers and a disturbed
regulation of the expression of several essential proteins such as
sarco-endoplasmic reticulum calcium ATPase (SERCA), calsequestrin
and calreticulin [38].Whether these alterations in skeletal muscles are
due to impaired gene expression as a result of a lack of glucocorticoids
during differentiation or whether they are caused by ER stress due to a
depletion of ER-lumenal NADPH, remains to be investigated.
Nevertheless, our results suggest that H6PDH is not the only
enzyme able to generate NADPH in the ER lumen. Using Western
blotting and MRM, we were not able to detect any endogenous
expression of H6PDH protein in our HEK-293 cells. Despite the lack of
endogenous H6PDH, 11β-HSD1 was able to catalyze both the
oxidation of cortisol and the reduction of cortisone. These observa-
tions suggest that there are other sources for NADPH generation in the
ER lumen, but that they play aminor role for 11β-HSD1 function under
physiological conditions. In fact, isocitrate dehydrogenase was
recently suggested to generate NADPH in the ER lumen [39]. The
isocitrate-dependent generation of NADPH in microsomes prepared
from rat liver and epididymal fat was almost completely latent,
indicating ER-lumenal localization of the activity. The impact of
isocitrate dehydrogenase activity on 11β-HSD1 function has not yet
been studied.
Interestingly, mutant Y18-21A predominantly catalyzed the
reductase reaction even in the absence of H6PDH, and coexpression
with H6PDH was not able to stimulate the reductase activity of the
mutant enzyme. As a possible explanation, NADPH available from
other sourcesmay be sufﬁcient to saturatemutant Y18-21A, which has
only about 20% of the activity of wild-type 11β-HSD1 in the absence of
H6PDH, while NADPH becomes limited for the fully functional wild-
type enzyme. In the presence of H6PDH, wild-type 11β-HSD1 has
approximately 20–30 times higher activity than mutant Y18-21A.
Another explanation could be that substitution of the four tyrosine
residues by alanine in the transmembrane helix locks the mutant
enzyme in a conformation that favors binding of NADPH. Recent
kinetic analyses indicated an ordered sequential bi–bi mechanism
with NADPH binding ﬁrst to the active site in 11β-HSD1, followed by
binding of cortisone [40,41]. If 11β-HSD1 exists in a complex with
H6PDH at the ER membrane, interaction with H6PDH might induce a
conformational change in 11β-HSD1 that favors binding of NADPH,
whereby the mutant enzyme might be stabilized in this conformation
even in the absence of H6PDH. Despite approximately ten-times
stronger interactionwith H6PDH comparedwith wild-type 11β-HSD1,
the reductase activity of mutant Y18-21A was not stimulated by
H6PDH. Thus, the additional NADPH produced locally by H6PDH did
not further enhance reductase activity, indicating that the cofactor
was not a limiting factor for the mutant enzyme under the conditions
applied.
Unfortunately, the 11β-HSD1/11β-HSD2 chimeric enzyme that lost
the interaction with H6PDH as well as several deletion mutants were
catalytically inactive. The enzymatic activity of the Y18-21A mutant
was also decreased, despite a stronger interaction with H6PDH,
suggesting that 11β-HSD1 enzymatic activity is tightly regulated by or
highly sensitive to conformational changes. In addition, a series ofsingle point mutations in the N-terminal post-transmembrane region
did not disrupt the interaction with H6PDH (data not shown),
suggesting that several residues of 11β-HSD1 are involved in the
interaction with H6PDH. Thus, in future experiments various
combinations of amino acid substitutions have to be analyzed to pin
point the exact interaction mechanism.
The protein–protein interaction allows a direct coupling of
glucose-6-phosphate availability via H6PDH-dependent NADPH gen-
eration with the activation of glucocorticoids in the ER lumen.
Glucocorticoids obtained their name because they are produced in
the adrenal cortex and regulate glucose production [42]. Thus, it is not
surprising that these glucose-regulating hormones themselves are
controlled by the intracellular glucose status, allowing a ﬁne-tuned
control of energy metabolism and adding another level of tissue- and
cell-speciﬁc regulation of glucocorticoid sensitivity. In a recent study,
Marcolongo et al. demonstrated that inhibition of the glucose-6-
phosphate transporter in the ER membrane decreased 11β-HSD1
reductase activity, probably due to a diminished supply of cofactor
NADPH as a result of the limited availability of glucose-6-phosphate in
the ER lumen [33]. Whether post-translational modiﬁcation regulates
the interaction between 11β-HSD1 and H6PDH, thereby controlling
local glucocorticoid activation independent of H6PDH effects on other
ER-lumenal enzymes, remains to be investigated.
Recently, the glucose-6-phosphate transporter and H6PDH have
been suggested as potential pharmacological targets for modulating
local glucocorticoid activation [33]. Based on the present study, we
suggest that the development of therapeutics disrupting the protein–
protein interaction between 11β-HSD1 and H6PDH offers an interest-
ing alternative approach to decrease 11β-HSD1 reductase activity
without affecting other H6PDH-dependent functions.
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